Moderna, Harwell, Oxfordshire

Glencar has been awarded the contract to construct a new Moderna Innovation and Technology centre (MITC) at the Harwell Health Technology Campus in Oxfordshire.

The MITC development will encompass a research, development and manufacturing facility, providing the UK public with access to cutting-edge mRNA vaccines for a wide range of respiratory diseases, pending regulatory assessment and licensure.
The new facility will also include a clinical biomarker laboratory -a prefabricated modular laboratory constructed in Northumberland which will then be installed on the campus.

Commenting on the project Eddie McGillycuddy, CEO said: “Having successfully delivered The Vaccine Manufacturing and Innovation Centre (VMIC), which was later acquired by Catalent, Glencar established a life sciences office within the Harwell Science and Innovation Campus to expand our portfolio in this sector and important location. With this in mind, we are absolutely delighted to now be delivering this pioneering research and development facility for Moderna.

Life science and pharmaceutical projects are complex, controlled environments that require significant design and engineering ability to ensure they delivered correctly. We have expanded our specialist team within this space to push forward and make these facilities a cornerstone of our continued growth in the coming years.

We very much look forward to working with the team at Moderna and Merit to develop this important new facility and the further expansion of the thriving health tech cluster at Harwell”.